Have any questions? 706-721-6582 or cts@augusta.edu
- ABL001E2201 (ASC4MORE): A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response
Clinical Trial
ABL001E2201 (ASC4MORE): A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response
Patients are being asked to take part in this study because they have chronic myeloid leukemia in chronic phase (CML-CP); cancer of the blood). The purpose of the study is to compare the benefits and side effects of asciminib added to imatinib versus imatinib alone or nilotinib in patients with CML in chronic phase who have been previously treated with imatinib.
- Circulatory System
- Cancer
- Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
- Hematologic Malignancies
- Leukemia
Eligibility Criteria
- Male or female, aged 18 years or older Subjects with confirmed chronic myeloid leukemia in chronic phase (CML-CP) A minimium of 12 months treatment with imatinib first line for CML-CP Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
RESEARCH. INNOVATION. DISCOVERY.